Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6002 + SG001 in advanced urothelial cancer and other solid tumors
ChiCTR2500107496Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CRB-701 and PBI-1308 in transitional cell carcinoma (TCC) and Nonhematologic neoplasms, sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Adverse events (AE), Serious adverse events (SAE) and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
CRB-701PBI-1308
03
Conditions
transitional cell carcinoma (TCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500107496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107496.